Investigation and Prosecution of Those Individuals Responsible for
Crimes Against Humanity
29 September 2021
The International Criminal Court
Office of the Prosecutor
Post Office Box 19519
2500 CM The Hague
The Netherlands
And
Ms. Karen Mosoti, or official replacement for the office of
Liaison Office of the International Criminal Court to the United Nations
866 United Nations Plaza
Suite 476
New York, NY, 10017
USA
212-486-1346/47/62
Email: otp.informationdesk@icc-cpi.int
Dear International Criminal Court and Prosecutor of the International Criminal Court, Mr. Karim Khan, and Ms. Karen Mosoti,
The following signatories submit to the International Criminal Court (ICC) and the Office of the Prosecutor, this Letter in Support of:
(1) The Joint Request for Investigation from the United Kingdom submitted by attorneys Melinda Mayne, Kaira S. McCallum (143/21), Slovakia submitted by attorneys Peter Weis, Marica Pirosikova, Erik Schmidt (133/21), France submitted by attorneys Patrice Lepiller, Raphael Cohen (271/21), and the Czech Republic submitted by attorney Tomas Nielsen (326/21) submitted to this Court on 12 August 2021.
(2) The Sworn Affidavits of Drs/PhDs. Richard M. Fleming, Luc Montagnier, and Kevin McCairn submitted with this Joint Request.
(3) Letter of Support by Nazi Concentration Camp Survivors Moshe Brown, Hillel Handler, and Vera Sharav submitted 20 September 2021.
In each instance the material, affidavits, and evidence provided substantiate information demonstrating Crimes Against Humanity by the Perpetrators including but not limited to violations of:
(1) The 1947 Nuremberg Code
(2) The 1964 Declaration of Helsinki
(3) The 1967 International Covenant on Civil and Political Rights, and
(4) The 1975 Biological Weapons Convention Treaty
We call upon the ICC and the Office of the Prosecutor of the ICC, and the United Nations Liaison Office of the ICC, to forthwith accept the Joint Request for Investigation, the Sworn Affidavits, the Nazi Concentration Camp Survivors’ Letter of Support, and supporting documents and materials, and to begin the Investigation and Criminal Prosecution of those individuals identified in the submitted documents, and those individuals identified in the interrogatories, depositions and investigation of those so identified.
Sign this petition by going to this link: https://www.petitions.net/investigation_and_prosecution_of_those_individuals_responsible_for_crimes_against_humanity
Richard M Fleming, PhD, MD, JD Contact the author of the petition
Go to Richard M Fleming’s website https://www.flemingmethod.com/
See also: https://peoplesworldwar.com/dr-richard-fleming-severe-criminal-violations/
More Information From Dr. Richard Fleming’s Website
DOCUMENTATION
The following diagram shows how SARS-CoV-2 is passed from person to person through respiratory droplets. Once inside the body the virus will invade our cells and reproduce itself. In response to the virus our immune system will attack the invader launching first a response from T-cells designed to kill the cells infected with the virus and later an antibody response designed to kill the virus before it gets into another cell.
This diagram also shows how too much of a good thing can cause harm to the body. When our VIRAL immune response, either because of other health problems we have (comorbidities) produce too much response OR because there is too much of the virus (e.g. vaccines) in our body; the outcome is INFLAMMATION and BLOOD CLOTTING [InflammoThrombotic Response – ITR] that can kill us (COVID-19).
The document numbers listed on the diagram below match the numbered documents providing links to the research as well as other materials not only explaining these issues but also the Gain-of-Function (GoF) research responsible for the development of this man-made virus.
SARS-CoV-2: Documents 17, 20. 144, 145, 146, 147, 148, 153, 156, 163, 164, 165, 169, 170, 182, 193, 194, 199, 209, 210, 212, 213, 214.
InflammoThrombotic Response (ITR): Documents 18, 19, 21, 33, 37, 49.
Treatment Information & Immunity: Documents 40, 67, 68,
69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 151, 152, 161, 162, 168, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 183, 186, 187, 205, 206, 207, 208, 211.
Gain-of-Function (With HIV-gp120; PRRA & Prion-like Domain): Documents 7, 9, 14, 15, 16, 21, 22, 26, 35, 36, 38, 39, 41, 42, 43, 44, 45, 46, 47, 48, 50, 54, 56, 57, 160, 166, 184, 215.
BIOWEAPON: 58, 59, 60, 61, 62.
Vaccines: Documents 1, 2, 3, 13, 24, 31, 32, 51, 52, 53, 55, 56, 65.
143, 149, 150, 154, 155, 158, 159, 167, 185, 188, 189, 190, 191, 192, 195, 196, 197, 198, 200, 201, 202, 203, 204, 207,
Enters Nucleus with DNA: Documents 10, 11, 12, 63, 64, 66, 157.
Antibody Dependent Enhancement of Virus: Documents 4, 5, 6, 167.
Neurologic – Central Nervous System – Brain: 8, 23, 25, 27, 28, 29, 30, 34.
1. EUA Requirements by FDA
October 2020
2. Pfizer EUA document
December 10, 2020
3. Moderna EUA Document
December 17, 2020
4. SARS-CoV-1 Antibody Dependent Enchancement (ADE)
July 5, 2011
5. ADE shown in animals including primates
January 2, 2021
6. ADE (Osaka Paper) showing antibodies to NTD increase infectivity of SARS-CoV-2
December 18, 2020
7. Prion-like Domains
March 29,, 2020
8. Amyloid Precursor Proteins and Neurologic Disease
May 21, 2019
9. Amyloidosis and Prion Diseases
October 26, 2010
10. SARS-CoV-2 RT back into human DNA
December 13, 2020
11. Platlets and LINE-1 to Generate RNA-DNA Hybrids with Reverse Transcriptase
April 2018
12. Reverse Transcription Produces Mechanism for Long Term Survival and Recurrent Infections
January 9, 2019
13. Pfizer vaccines contains 13 billion mRNA repetitions in the low dose of 30-micrograms.
December 25, 2020
14. Baric & Zhengli Shi re-engineer the HKU4 spike to increase Corona Virus Infectivity. Gain-of-Function (GoF)
September 2015
15. SARS-CoV-2 Gain-of-Function Hall of Shame
October 1, 2020
16. Evidence that SARS-CoV-2 is not naturally evolved
July 1, 2020
17. South African Mutation of SARS-CoV-2
December 22, 2020
18. InflammoThrombotic Response (ITR)
August 18,2020
19. Massive Blood Clots Kill COVID Patients
August 18, 2020
20. Cryo-Electron Tomography of SARS-CoV-2 showing spike proteins
October 9, 2020
21. PRRA Superantigen increases inflammation
October 13, 2020
22. PRRA Insert essential for infection of human lung cells and brain
May 1, 2020
23. SARS-CoV-2 Spike protein crosses the blood brain barrier in mice study
December 16, 2020
24. Neurological adverse events associated with vaccines
June 2002
25. SARS-CoV-2 Invades Brain
November 30, 2020
26. Neuropilin-1binds to Furin (PRRA) Cleavage site to increase Infectivity.
November 13, 2020
27. Spike Protein Crosses BBB to Infect Brain
November 30, 2020
28. Fatal Invasion of Brain by SARS-CoV-2 Depends upon ACE2.
January 15, 2021
29. SARS-CoV-2 Interferes With Recognition of the Severity of Hypoxemia.
July 28, 2020
30. RNA can Behave like Prions.
July 1, 2020
31. Influenza mRNA Spreads Throughout Body and Found in Lungs, Brain, Heart for 14-days.
October 1995
32. Moderna mRNA Vaccine for Influenza Spreads Throughout Body.
March 24, 2017
33. How Immune Cells Cross the Blood-Brain Barrier.
February 4, 2019
34. Neuroinvasion, Encephalitis and Neuron Death with SARS-CoV-2.
January 19, 2021
35. Jean claude Perez § Luc Montagnier – COVID-19, SARS and Bats Coronaviruses Genomes Unexpected Exogenous RNA Sequences
May 29, 2020
36. Jean claude Perez § Luc Montagnier – COVID-19, COVID-19, SARS and Bats Coronaviruses Genomes Peculiar Homologous RNA Sequences
July 7, 2020
37. Autopsy Findings of InflammoThrombotic Response (ITR) in Patients with COVID-19
JAugust 18, 2020
38. TMPRSS2 and Furin Both Essential for SARS-CoV-2 Infection of Cells.
July 23, 2020
39. Protein structure and sequence re-analysis of 2019-nCoV genome does not indicate snakes as its intermediate host or the unique similarity between its spike protein insertions and HIV-1
March 22, 2020
40. Treatment of SARS-CoV-2 & COVID-19.
February 8, 2021
41. Evidence of Gain-of-Function.
September 14, 2020
42. Gain-of-Function Hall of Shame.
October 1, 2020
43. Origins of SARS-CoV-2.
February 7, 2021
44. Genetic Structure of SARS-CoV-2.
October 16, 2020
45. Origins of SARS and PRRA.
August 12, 2020
46. The Corona Conspiracy.
October 2020
47. Probabilities of SARS-CoV-2 Origin.
November 12, 2020
48. The Fauci COVID-19 Dossier.
February 18, 2021
49. Primate studies show Inflammation in Brain & Lewy Bodies.
February 23, 2021
50. Patent for PRRA Furin Cleavage Site with Certain Patent Rights Owned by U.S. Governmnent (NIH).
May 29, 2007
51. Janssen (Johnson & Johnson) EUA Document.
February 26, 2021
52. Ad26 [J & J] Prior Studies Reveal Only Temporary Immunity.
July 18, 2012
53. The Coxsackie & Adenovirus Receptor (CAR).
June 8, 1999
54. Deleted Wuhan Databases.
February 23, 2021
55. CDC Document on Adenovirus Vaccines.
January 8, 2020
56. COVID-19 Vaccines and Brain Injury.
April 10, 2021
57. SARS-CoV-2 Accelerates Amyloid Formation.
April 12, 2021
58. SARS-CoV-2 Is an Unrestricted Bioweapon.
Released April 24, 2021
59. SARS-CoV-2 is a Sophisticated Lab Modification.
Released April 24, 2021
60. CNN Lies and Misinformation.
September 14, 2020
61. SARS-CoV-2 – A Scientific Discussion of Lab Origin.
March 25, 2021
62. Lethal Deception.
April 22, 2021
63. Reverse Transcription of SARS-CoV-2 in Human Cells.
March 29, 2021
64. Evidence in Support of SARS-CoV-2 (Viral)-Human Cell Chimers.
March 29, 2021
65. Rethinking Vaccine Safety.
June 24, 2021
66. SARS-CoV-2 Reverse Transcription (RT) Integration into Human DNA.
May 6 , 2021
67. Immunity to SARS-CoV-2 Independent of Severity of SARS-CoV-2/COVID-19 Infection.
June 4, 2021
68. Italian Treatment Recommendations.
March 20, 2021
69. Commenting on Chloroquine.
March 2, 2020
70. Interleukin-6 (IL-6) levels.
April 11, 2020
71. Hydroxychloroquine (HCQ).
April 14, 2020
72. ACEI & ARBs.
May 8, 2020
73. Anti-virals.
January 27, 2020
74. Masks.
April 6, 2020
75. IL-6 Inhibitors.
May 29, 2020
76. Quantitative Nuclear Imaging of Disease.
July 24, 2019
77. Treating QTc Prolongation.
June 25, 2009
78. Hydroxychloroquine better than Chloroquine.
March 14, 2020
79. Nuclear Imaging of Infections.
January 1, 2008
80. Toll-like Receptors.
January 1, 2008
81. Nebulized Azithromycin.
2019
82. Mesenchymal Stem Cells.
February 18, 2020
83. TMPRSS2 and Furin Cleavage Receptors.
May 20, 2020
84. Hydroxychloroquine and Azithromycin.
April 1, 2020
85. Cuban Interferon.
March 13, 2020
86. IL-6 levels Predict Respiratory Failure.
April 1, 2020
87. Vitamin D and Steroids.
April 2020
88. Quantifying Changes in Disease & Treatment Outcomes.
January 17, 2020
89. Ivermectin Protects Nuclear Pore Complex (NPC).
March 29, 2020
90. Convalescent Plasma.
April 3, 2020
91. Multiple Drug Considerations.
May 12, 2020
92. Early Results of Convalescent Plasma.
April 13, 2020
93. N-95 Masks.
February 12, 2020
94. Face Masks in Symptomatic Individuals.
April 10, 2020
95. Decreasing Ventilator Tidal Volume (TV) to Reduce Deaths.
May 4, 2000
96. Lopinavir-Ritonavir Not Successful.
May 7, 2020
97. Reduce TV on Ventilators for Patients with ARDS to Reduce Deaths.
July 22, 2004
98. Remdesivir.
April 10, 2020
99. ACEI and ARBs in the Patients with Heart Disease.
May 1, 2020
100. Multiple Treatment Considerations.
April 28, 2020
101. Rethinking ACEI and ARBS.
April 23, 2020
102. Simple Ventilator & Breathing Terms for Students Using Ventilators.
2008
103. Prone Positioning of Patients Saves Lives.
June 6, 2013
104. Prone Positioning of Patients.
April 8, 2020
105. Remdesivir.
June 2020
106. Treating the InflammoThrombotic Response (ITR).
May 6, 2020
107. SARS-CoV-2 Genome.
May 4, 2020
108. Neutralizing Antibodies.
May 18, 2020
109. Transmission of SARS-CoV-2.
April 15, 2020
110. Centers for Disease Control (CDC) & Emergency Use Authorization (EUA).
April 13, 2020
111. ACEI and ARBs in the Patients with Hypertension (High Blood Pressure).
April 22, 2020
112. Nebulized Antibiotics.
June 2015
113. Nebulized Antibiotics with Lung Disease.
April 1, 2016
114. Thinking About the Pharmacodynamics of Antibiotics.
Deember 12, 2011
115. Immune Response and Various Antibiotics.
December 2015
116. Azithromycin and Zika Virus.
December 13, 2016
117. Doxycycline.
May 9, 2020
118. Aminoquinolines.
April 7, 2020
119. Chloroquine Zinc Ionophore.
October 1, 2014
120. Transmembrane protease serine 2 (TMPRSS2).
April 16, 2020
121. Hydroxychloroquine – NOT alone.
April 16, 2020
122. Primaquine and Newcastle Virus.
October 1974
123. Convalescent Plasma and Viral Infections.
January 1, 2015
124. Neutralizing Antibodies.
March 15, 2020
125. Esmolol for QTc Prolongation.
March 13, 2020
126. Drugs to Avoid with Long QT Syndrome.
April 26, 2013
127. Tocilizumab.
2020
128. Tocilizumab is Effective for ITR.
April 14, 2020
129. Tocilizumab Treatment of COVID-19 Respiratory Failure.
March 27, 2020
130. Tocilizumab and Castleman Disease.
November 2008
131. Janus Kinases.
November 30, 2004
132. Interferon Combination Therapies.
May 8, 2020
133. QTc Prolongation and Tachycardia with Ventolin (Albuterol).
June 28, 2016
134. Chloroquine Reduces Interleukins.
November 29, 2005
135. Zinc (Zn++) Ionophore.
April 9, 2020
136. Interleukin-6 (IL-6) and Steroid Resistance.
December 26, 2012
137. Inhaled Corticosteroids.
March 8, 2010
138. Inhaled Methylprednisolone.
March 30, 2020
139. Innate Immunity.
June 17, 2014
140. Clindamycin and TMPRSS2.
February 18, 2020
141. Heparin Inhibits S1 Spike Protein Attachment to Heparin Binding Protein Site of Regional Binding Domain (RBD).
June 6, 2020
142. Measuring PCR & The Importance of Providing Successful Treatments – Fleming Treatments Recognized Internationally.
July 1, 2021
143. Graphene Oxide Disrupt SARS-CoV-2 Ability to Infect.
May 14, 2021
144. 30,091SARS-CoV-2 Nucleotide Bases.
July 14, 2021
145. The SARS-CoV-2 Virus.
June 2020
146. Recovery of Wuhan Lab Data.
June 22, 2021
147. 283 SARS-CoV-2 Case Information.
March 31, 2020
148. SARS-CoV-2-WA/CDC.
July 29, 2020
149. COVID-19 Vaccine Associated Parkinson’s Disease, A Prion Disease Signal in the UK Yellow Card Adverse Event Database.
July 18, 2021
150. Pfizer UK Yellow Card Adverse Event Data.
June 30, 2021
151. Unexpected SARS-CoV-2 RNA Sequences.
May 30, 2020
152. Mask Analysis of SARS.
August 7, 2017
153. Fibonacci Analysis of SARS-CoV-2 Variants and Vaccine mRNA Spikes.
June 30, 2021
154. COVID-19 RNA Based Vaccines and Prion Disease.
January 18, 2021
155. Review of COVID Vaccines and Risk of Adverse Events Including Neurologic Disease.
April 10, 2021
156. Mullis PCR Patent.
July 28, 1987
157. Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues.
May 6, 2021
158. Shedding is defined by FDA, HHS, and the Center for Biologics Evaluation and Research.
(Look at the foot notes at the bottom of page 9).
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-and-analysis-shedding-studies-virus-or-bacteria-based-gene-therapy-and-oncolytic-products
January 2020
159. SARS-CoV-2 Drug Vaccine Biologics are Gene Therapy According to FDA definition.
July 25, 2018
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy
160. Daszak & Zhengli build a Gain-of-Function Coronavirus that inhibits protective human immune response. Paid for by NIAID.
May 11, 2016
161. Natural IgG and IgA Immunity Following Infection with SARS-CoV-2.
May 7, 2021
162. T-cell Receptor (TCR) Immunity to SARS-CoV-2 Following Infections with Influenza or Cytomegalovirus (CMV).
June 23, 2021
163. SARS-C0V-2 Isolation Sequence & Primers.
April 12, 2020
164. Original Chinese Patients with SARS-CoV-2.
January 24, 2020
165. Appendix for # 164.
January 24, 2020
166. SARS-CoV-2 Prion-like Domain (PLD) Increases Infectivity of this Virus.
March 29, 2020
167. Patients are NOT Receiving Adequate Informed Consent.
December 4, 2020
168. Evidence of Long Term Durable Natural Immunity to SARS-CoV-2 Following Infection.
July 20, 2021
169. SARS-CoV-2 Bayesian Analysis Concludes SARS-CoV-2 Was NOT Natural BUT Laboratory Developed.
January 29, 2021
170. House Foreign Affairs Committee Report Minority Staff. Origins-of-COVID-19 Report.
August 2021
171. Harm Caused by Excluding Family Visitation.
January 11, 2021
172. Multiple Benefits to Patients with Family Visitation.
September 15, 2020
173. Supportive Evidence for Family ICU Visitation.
November 2011
174. The Importance of Family in Pediatric Cases.
May 6, 2020
175. Impact of Family Presence in the Healthcare Setting.
Spring 2014
176. Let Families into Intensive Care Units (ICUs).
March 6, 2016
177. The Family Needs of Intensive Care Unit (ICU) Patients.
March 25, 2019
178. Patients & Families of Intensive Care Unit (ICU) Patients.
April 6, 2018
179. Care & Caring in the Intensive Care Unit (ICU).
June 2016
180. Hospital Systems Have Chosen the Fear for Us.
October 21, 2020
181. Substantial Evidence Suggests Parental Visitation to Neonates (newborns) in Neonatal Intensive Care Units (NICU) Should NOT Change.
August 8, 2020
182. Aerosol Transmission of SARS-CoV-2?
August 7, 2020
183. Natural Immunity to Delta Variant Provides Stronger and Longer Lasting Immunity than Pfizer Vaccine.
August 25, 2021
184. Canadian Emails Re: Early Wuhan SARS-CoV-2 Genetic Modifications.
August 28, 2021
185. Both SARS-CoV-2 and the Vaccines Increase Risk of InflammoThrombotic Response (ITR) Disease (COVID-19).
August 25, 2021
186. The Importance of the Innate T-Cell Immune System in Children.
July 26, 2021
187. Antibodies to Spike Protein Can Cause Severe Acute (sudden) Lung Disease.
February 21, 2019
188. Pfizer Vaccine Interferes with Tdap Vaccine.
July 25, 2021
189. SARS-CoV-1 Vaccine Leads to Lung Disease.
April 20, 2012
190. Moderna Patent Shows Effect on Innate Immune Response (pp. 24 & 24).
July 7, 2020
191. Moderna Patent – Publication
November 12, 2020
192. Pfizer, Moderna & Janssen Drug Vaccines Cause More Harm than Good.
August 25, 2021
193. Beta (B.1.351) Variant Emerges in South Africa.
December 22, 2020
194. Morbidity and Mortality Weekly Report (MMWR) Reports that 74% of People with Delta (B.1.617.2) Variant in Massachusetts are Fully Vaccinated.
August 6, 2021
195. Israeli Data Shows Good Protection with Pfizer Two Dose Vaccinated People for Alpha (B.1.1.7) Variant.
May 15, 2021
196. Delta Variant (B.1.617.2) Surging in Israel In Spite of Pfizer Two Dose Vaccinations.
July 31, 2021
197. German Outbreak of Alpha (B.1.1.7) Variant Following Pfizer Two Dose Vaccinations.
August 2021
198. The Importance of Recognizing the Limitations of Spike Protein Regional Binding Domain (RBD) [e.g. nucleotide bases 318-510] Drug Vaccines. Another lesson forgotten: “with distinct genotypes”.
July 2005
199. Morbidity and Mortality Weekly Report (MMWR). U.S. HHS Knows About SARS-CoV-2 Variants.
January 22, 2021
200. Pfizer Vaccine Shown to Reduce Innate T-Cell Response.
October 22, 2020
201. Moderna (mRNA-1273) Vaccine Fails to Elicit Th2 Innate Immune Response Critical for B-Cell (antibody) Proliferation (increase) and Differentiation (Specific Antibody Production).
July 28, 2020
202. AstraZeneca (ChAdOx1 nCoV-19) Vaccine Results in Multiple Cebral (Brain) Venous (Veins) Thrombosis (Blood Clots).
September 2021
203. Chinese Drug Vaccine for SARS-CoV-1.
January 1, 2007
204. Pfizer Drug Vaccine Reprograms, in Some Instances Weakening, the Human Innate Immune Response to Multiple Pathogens.
May 6, 2021
205. Primaquine Inhibits Protein Biosynthesis (i.e. mRNA to Protein Translation). It’s more than just an anti-malarial.
January 26, 1972
206. Antibodies Produced Against Innate T-Cell Interferon Increases the Risk of InflammoThrombotic Response (ITR) Pulmonary Disease (COVID-19).
October 23, 2020
207. Antibody Dependent Enhancement (ADE) Antibodies are a Potential Risk Associated with Drug Vaccine Biologics.
August 16, 2021
208. Interferon-gamma Critical to Innate Immunity.
August 1983
209. The Glycan Gate & The Sialic Acid Raft Receptor.
August 19, 2021
210. Sialic Acid Raft Recptor (Neu5Ac) Emerging as Interface Between Infectious Disease, Biological Chemistry, and Nanoscience.
February 5, 2021
211. Ions Including Ca+2, Mg +2, and Zn+2 and Their Roles as Cofactors in Immunity.
June 2018
212. Baric Makes Complete Recombinant SARS Coronavirus.
October 28, 2003
213. Patent Links Baric’s Work with Transmissible Gastroenteritis Virus (TGV) and Recombinant Production of Coronavirus. Paid for by NIH Grants.
October 9, 2007
214. Intercept Newsroom “Understanding Risk Bat Coronavirus Emergence Grant Notice”.
September 2021
215. Method and Composition Patent for Chimeric Coronaviruses and Spike Proteins. NIH Grant U54AI057157.
February 6, 2018
The bottom portion of this page has been shared from https://www.flemingmethod.com/documentation
[…] Sign his petition here https://peoplesworldwar.com/petition-investigation-and-prosecution-of-those-responsible-for-crimes-… […]